AI diagnostics

Digital

On the sidelines of JPM2026, pharmaphorum spoke with Andrew Beck, co-founder and CEO at PathAI, about AI diagnostics in pathology.

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.